The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics

International Journal of Endocrinology

Volumn 2016, Issue , 2016, Pages

  Goldvaser, Hadar ^a   Rizel, Shulamith ^a,b   Hendler, Daniel ^a   Neiman, Victoria ^a   Shepshelovich, Daniel ^a,b   Shochat, Tzippy ^a   Sulkes, Aaron ^a,b   Brenner, Baruch ^a,b   Yerushalmi, Rinat ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; KI 67 ANTIGEN; LEVOTHYROXINE; METFORMIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DYSLIPIDEMIA; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOLOGY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OVERALL SURVIVAL; RECURRENCE SCORE; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; THYROID DISEASE; TUMOR VOLUME;

EID: 84987861813     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2016/4658469     Document Type: Article

References (53)

1. M. Cianfrocca and L. J. Goldstein, "Prognostic and predictive factors in early-stage breast cancer," Oncologist, vol. 9, no. 6, pp. 606-616, 2004.
2. C. W. Elston and I. O. Ellis, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup," Histopathology, vol. 19, no. 5, pp. 403-410, 1991.
3. M. Schumacher, C. Schmoor, W. Sauerbrei et al., "The prognostic effect of histological tumor grade in node-negative breast cancer patients," Breast Cancer Research and Treatment, vol. 25, no. 3, pp. 235-245, 1993.
4. P. L. Nguyen, A. G. Taghian, M. S. Katz et al., "Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy," Journal of Clinical Oncology, vol. 26, no. 14, pp. 2373-2378, 2008.
5. E. K. A. Millar, P. H. Graham, S. A. O'Toole et al., "Prediction of local recurrence, distant metastases, and death after breastconserving therapy in early-stage invasive breast cancer using a five-biomarker panel," Journal of Clinical Oncology, vol. 27, no. 28, pp. 4701-4708, 2009.
6. K. D. Voduc, M. C. U. Cheang, S. Tyldesley, K. Gelmon, T. O. Nielsen, and H. Kennecke, "Breast cancer subtypes and the risk of local and regional relapse," Journal of Clinical Oncology, vol. 28, no. 10, pp. 1684-1691, 2010.
7. S. F. Schoppmann, G. Bayer, K. Aumayr et al., "Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer," Annals of Surgery, vol. 240, no. 2, pp. 306-312, 2004.
8. S. E. Pinder, I.O. Ellis, M. Galea, S.O'Rourke, R.W. Blamey, and C. W. Elston, "Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up," Histopathology, vol. 24, no. 1, pp. 41-47, 1994.
9. S. Paik, S. Shak, G. Tang et al., "A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer," The New England Journal of Medicine, vol. 351, no. 27, pp. 2817-2826, 2004.
10. S. Paik, G. Tang, S. Shak et al., "Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer," Journal of Clinical Oncology, vol. 24, no. 23, pp. 3726-3734, 2006.
11. S. K. Garg, H. Maurer, K. Reed, and R. Selagamsetty, "Diabetes and cancer: two diseases with obesity as a common risk factor," Diabetes, Obesity and Metabolism, vol. 16, no. 2, pp. 97-110, 2014.
12. C. M. Kitahara, A. Berrington de González, N. D. Freedman et al., "Total cholesterol and cancer risk in a large prospective study in Korea," Journal of Clinical Oncology, vol. 29, no. 12, pp. 1592-1598, 2011.
13. E. R. Nelson, S. E. Wardell, J. S. Jasper et al., "27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology," Science, vol. 342, no. 6162, pp. 1094-1098, 2013.
14. S. S. Coughlin, E. E. Calle, L. R. Teras, J. Petrelli, and M. J. Thun, "Diabetes mellitus as a predictor of cancermortality in a large cohort of US adults," American Journal of Epidemiology, vol. 159, no. 12, pp. 1160-1167, 2004.
15. C.-H. Tseng, C.-K. Chong, and T.-Y. Tai, "Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006," Diabetologia, vol. 52, no. 2, pp. 240-246, 2009.
16. C.-H. Tseng, "Diabetes and breast cancer in Taiwanese women: a detectionbias?" European Journal of Clinical Investigation, vol. 44, no. 10, pp. 910-917, 2014.
17. N. Vrachnis, C. Iavazzo, Z. Iliodromiti et al., "Diabetes mellitus and gynecologic cancer:molecular mechanisms, epidemiological, clinical and prognostic perspectives," Archives of Gynecology and Obstetrics, vol. 293, no. 2, pp. 239-246, 2016.
18. S. S. Coughlin and S. A. Smith, "The Insulin-like growth factor axis, adipokines, physical activity, and obesity in relation to breast cancer incidence and recurrence," Cancer and Clinical Oncology, vol. 4, no. 2, pp. 24-31, 2015.
19. I. Ben Sahra, K. Laurent, A. Loubat et al., "The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level," Oncogene, vol. 27, no. 25, pp. 3576-3586, 2008.
20. I. N. Alimova, B. Liu, Z. Fan et al., "Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro," Cell Cycle, vol. 8, no. 6, pp. 909-915, 2009.
21. E. García-Esquinas, E. Guinó, G. Castaño-Vinyals et al., "Association of diabetes and diabetes treatment with incidence of breast cancer," Acta Diabetologica, vol. 53, no. 1, pp. 99-107, 2016.
22. D. Margel, D. R. Urbach, L. L. Lipscombe et al., "Metformin use and all-cause and prostate cancer-specificmortality amongmen with diabetes," Journal of Clinical Oncology, vol. 31, no. 25, pp. 3069-3075, 2013.
23. M. Yin, J. Zhou, E. J. Gorak, and F. Quddus, "Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and metaanalysis," The Oncologist, vol. 18, no. 12, pp. 1248-1255, 2013.
24. C.-H. Tseng, "Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes," Breast Cancer Research and Treatment, vol. 145, no. 3, pp. 785-790, 2014.
25. S. Jiralerspong, S. L. Palla, S. H. Giordano et al., "Metforminand pathologic responses to neoadjuvant chemotherapy in diabetic patients with breast cancer," Journal of Clinical Oncology, vol. 27, pp. 3297-3302, 2009.
26. H. Xu, K. Chen, X. Jia et al., "Metformin use is associated with better survival of breast cancer patients with diabetes: a metaanalysis," Oncologist, vol. 20, no. 11, pp. 1236-1244, 2015.
27. J. Kim, W. Lim, E.-K. Kim et al., "Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)," BMC Cancer, vol. 14, no. 1, article 170, 2014.
28. B. A. Oppong, L. A. Pharmer, S. Oskar et al., "The effect of metformin on breast cancer outcomes in patients with type 2 diabetes," Cancer Medicine, vol. 3, no. 4, pp. 1025-1034, 2014.
29. T. Yang, Y. Yang, and S. Liu, "Association between metformin therapy and breast cancer incidence and mortality: evidence from a meta-analysis," Journal of Breast Cancer, vol. 18, no. 3, pp. 264-270, 2015.
30. B. Kowall, A. Stang, W. Rathmann, and K. Kostev, "No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK," Pharmacoepidemiology and Drug Safety, vol. 24, no. 8, pp. 865-874, 2015.
31. M. Janghorbani, M. Dehghani, and M. Salehi-Marzijarani, "Systematic review and meta-analysis of insulin therapy and risk of cancer," Hormones and Cancer, vol. 3, no. 4, pp. 137-146, 2012.
32. Ø. Karlstad, J. Starup-Linde, P. Vestergaard et al., "Use of insulin and insulin analogs and risk of cancer-systematic review and meta-analysis of observational studies," Current Drug Safety, vol. 8, no. 5, pp. 333-348, 2013.
33. I. N. Colmers, S. L. Bowker, L. A. Tjosvold, and J. A. Johnson, "Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies," Diabetes & Metabolism, vol. 38, no. 6, pp. 485-506, 2012.
34. H. K. Bronsveld, B. ter Braak, Ø. Karlstad et al., "Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence," Breast Cancer Research, vol. 17, article 100, 2015.
35. N. Ghosh-Choudhury, C. C. Mandal, N. Ghosh-Choudhury, and G. Ghosh Choudhury, "Simvastatin induces derepression of PTEN expression viaNFκB to inhibit breast cancer cell growth," Cellular Signalling, vol. 22, no. 5, pp. 749-758, 2010.
36. K. K. W. Chan, A. M. Oza, and L. L. Siu, "The statins as anticancer agents," Clinical Cancer Research, vol. 9, no. 11, pp. 10-19, 2003.
37. M. J. Campbell, L. J. Esserman, Y. Zhou et al., "Breast cancer growth prevention by statins," Cancer Research, vol. 66, no. 17, pp. 8707-8714, 2006.
38. Y. H. Park, H. H. Jung, J. S. Ahn, and Y.-H. Im, "Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway," Biochemical and Biophysical Research Communications, vol. 439, no. 2, pp. 275-279, 2013.
39. A. Gopalan, W. Yu, B. G. Sanders, and K. Kline, "Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway," Cancer Letters, vol. 329, no. 1, pp. 9-16, 2013.
40. S. Zhong, X. Zhang, L. Chen, T. Ma, J. Tang, and J. Zhao, "Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies," Cancer Treatment Reviews, vol. 41, no. 6, pp. 554-567, 2015.
41. S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras, "Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies," Journal of Clinical Oncology, vol. 23, no. 34, pp. 8606-8612, 2005.
42. K. Undela, V. Srikanth, and D. Bansal, "Statin use and risk of breast cancer: a meta-analysis of observational studies," Breast Cancer Research and Treatment, vol. 135, no. 1, pp. 261-269, 2012.
43. J. A. McDougall, K. E. Malone, J. R. Daling, K. L. Cushing-Haugen, P. L. Porter, and C. I. Li, "Long-termstatin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age," Cancer Epidemiology Biomarkers and Prevention, vol. 22, no. 9, pp. 1529-1537, 2013.
44. P. Desai, A. Lehman, R. T. Chlebowski et al., "Statins and breast cancer stage and mortality in the Women's Health Initiative," Cancer Causes and Control, vol. 26, no. 4, pp. 529-539, 2015.
45. C.R. Cardwell, B.M. Hicks, C. Hughes, and L. J. Murray, "Statin use after diagnosis of breast cancer and survival: a populationbased cohort study," Epidemiology, vol. 26, no. 1, pp. 68-78, 2015.
46. A. Tosovic, C. Becker, A.-G. Bondeson et al., "Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk," International Journal of Cancer, vol. 131, no. 9, pp. 2126-2133, 2012.
47. A. Tosovic, A.-G. Bondeson, L. Bondeson, U.-B. Ericsson, J. Malm, and J. Manjer, "Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women," Breast Cancer Research, vol. 12, no. 3, article R33, 2010.
48. J. Brandt, S. Borgquist, and J. Manjer, "Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to risk of different breast cancer subgroups: a Malmö Diet and Cancer Study," Cancer Causes and Control, vol. 26, no. 8, pp. 1093-1104, 2015.
49. M. Søgaard, D. K. Farkas, V. Ehrenstein, J. O. Jørgensen, O. M. Dekkers, and H. T. Sørensen, "Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study," European Journal of Endocrinology, vol. 174, no. 4, pp. 409-414, 2016.
50. Y.K. Chae, M. E. Valsecchi, J. Kimet al., "Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins," Cancer Investigation, vol. 29, no. 9, pp. 585-593, 2011.
51. S. Bangalore, S. Kumar, S. E. Kjeldsen et al., "Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials," The Lancet Oncology, vol. 12, no. 1, pp. 65-82, 2011.
52. C.-H. Tseng, "Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes," BMC Cancer, vol. 15, article 846, 2015.
53. C.-H. Tseng, "Use of insulin and mortality from breast cancer among Taiwanese women with diabetes," Journal of Diabetes Research, vol. 2015, Article ID 678756, 8 pages, 2015.